| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), NVAX's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 300.3K | - | - | |
| VP | 157.1K | - | - | |
| CFO | 136.5K | - | - | |
| VP | 101.4K | - | - | |
| Dir | 73.2K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2016 | Evans Gary C | Director | Sell | 18,998 | $6.50 | $123,487.00 | -5.6% | |
| May 24, 2016 | Evans Gary C | Director | Sell | 50,000 | $5.41 | $270,371.08 | -12.8% | |
| Mar 31, 2016 | Erck Stanley C86 | President And CEO | Sale+OE | 424,778 | $5.19 | $2,203,619.18 | -84.4% | |
| Jan 31, 2016 | Trizzino John86 | SVP, Commercial Operations | Buy | 5,855 | $3.63 | $21,253.65 | +17.4% | |
| Jan 31, 2016 | Herrmann John A III91 | SVP, General Counsel | Buy | 2,072 | $4.38 | $9,075.36 | +5,180% | |
| Jan 31, 2016 | Glenn Gregory M88 | SVP, Research And Development | Buy | 2,369 | $4.38 | $10,376.22 | +4,084% | |
| Jan 31, 2016 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 405 | $4.38 | $1,773.90 | +4.4% | |
| Jan 31, 2016 | Erck Stanley C86 | CEO And President | Buy | 2,072 | $4.38 | $9,075.36 | +2.1% | |
| Dec 16, 2015 | Glenn Gregory M88 | SVP, Research And Development | Sale+OE | 61,886 | $8.58 | $530,697.20 | -99.9% | |
| Dec 16, 2015 | Herrmann John A III91 | SVP, General Counsel | Sell | 27,945 | $8.64 | $241,419.65 | -99.9% |